Literature DB >> 14679425

Viral hepatitis in the Canadian Inuit and First Nations populations.

Gerald Y Minuk1, J Uhanova.   

Abstract

OBJECTIVE: To review published prevalence data regarding hepatitis A (HAV), B (HBV) and C (HCV) in Canadian Inuit and First Nations populations.
METHODS: PubMed database search and review of all papers describing data derived from seroepidemiological surveys.
RESULTS: The prevalence of anti-HAV positivity in Canadian Inuit and First Nations populations reported to date is high (range 75% to 95%) and approximately three times that of non-Aboriginal Canadians residing in the same communities. Among the Canadian Inuit, the prevalence of HBV infection is approximately 5%, or 20 times that of non-Aboriginal Canadians, while the risk of exposure to HBV is 25%, or five times higher. Regarding the First Nations population, preliminary data suggest the prevalences of HBV infection (0.3% to 3%) and exposure (10% to 22%) are similar to rates in non-Aboriginals residing in the same regions and participating in similar high risk activities. Serological evidence of HCV infection (anti-HCV) is more common in the Canadian Inuit and First Nations (1% to 18%) than the remainder of the Canadian population (0.5% to 2%); however, viremia (HCV-RNA positivity) is less common (less than 5% versus 75% of anti-HCV positive individuals, respectively).
CONCLUSIONS: Viral hepatitis is common in the Canadian Inuit and First Nations populations. In the absence of coexisting human immunodeficiency virus infection and alcohol abuse, the outcomes of HBV and HCV appear to be more benign than in non-Aboriginal Canadians.

Entities:  

Mesh:

Year:  2003        PMID: 14679425     DOI: 10.1155/2003/350175

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  21 in total

Review 1.  The role of seroepidemiology in the comprehensive surveillance of vaccine-preventable diseases.

Authors:  Sarah E Wilson; Shelley L Deeks; Todd F Hatchette; Natasha S Crowcroft
Journal:  CMAJ       Date:  2011-11-14       Impact factor: 8.262

2.  Hepatitis B prevention and control: Lessons from the East and the West.

Authors:  Monica C Robotin
Journal:  World J Hepatol       Date:  2011-02-27

3.  Vertical transmission of the hepatitis C virus: Current knowledge and issues.

Authors: 
Journal:  Paediatr Child Health       Date:  2008-07       Impact factor: 2.253

4.  Ethnicity and spontaneous clearance of hepatitis C in HIV-HCV coinfected patients.

Authors:  Lil Miedzinski; Geoff Taylor
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-07       Impact factor: 2.471

5.  The potential influence of KIR cluster profiles on disease patterns of Canadian Aboriginals and other indigenous peoples of the Americas.

Authors:  Julia D Rempel; Kim Hawkins; Erin Lande; Peter Nickerson
Journal:  Eur J Hum Genet       Date:  2011-07-06       Impact factor: 4.246

6.  Liver transplant outcomes in a Canadian First Nations population.

Authors:  M Zhang; J Uhanova; G Y Minuk
Journal:  Can J Gastroenterol       Date:  2011-06       Impact factor: 3.522

7.  A mathematical model to study the effect of hepatitis B virus vaccine and antivirus treatment among the Canadian Inuit population.

Authors:  C O'Leary; Z Hong; F Zhang; M Dawood; G Smart; K Kaita; J Wu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-12       Impact factor: 3.267

Review 8.  Chronic liver disease in Aboriginal North Americans.

Authors:  John D Scott; Naomi Garland
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

9.  Treatment of chronic hepatitis C in a Canadian Aboriginal population: results from the PRAIRIE study.

Authors:  Gerald Y Minuk; Meaghan O'Brien; Kim Hawkins; Didi Emokpare; James McHattie; Paul Harris; Lawrence Worobetz; Karen Doucette; Kelly Kaita; Stephen Wong; Gilles Pinette; Julia Uhanova
Journal:  Can J Gastroenterol       Date:  2013-12       Impact factor: 3.522

10.  Hepatitis C Virus Infection in Indigenous Populations in the United States and Canada.

Authors:  Veronica Bruce; Jonathan Eldredge; Yuridia Leyva; Jorge Mera; Kevin English; Kimberly Page
Journal:  Epidemiol Rev       Date:  2019-01-31       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.